Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05067140 · ClinicalTrials.gov registry record · Phase 1
A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
A Phase 1 study of Prostate Cancer Metastatic, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 1
- Development phase
- 152
- Enrollment target
- 20
- Study locations
NCT05067140: Active Phase 1 study of Prostate Cancer Metastatic, sponsored by Novartis Pharmaceuticals.
NCT05067140 is a Phase 1 study of Prostate Cancer Metastatic that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 152 participants, below the 219-participant average among 17 other Prostate Cancer Metastatic trials with a reported enrollment target (31% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05067140, a Phase 1 study of Prostate Cancer Metastatic, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 152 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 1/2 study to evaluate the safety and efficacy of ARV-766 given by mouth alone or in combination with abiraterone in men with metastatic prostate cancer.
Primary Outcome
Number and proportion of participants experiencing dose-limiting toxicities during the DLT evaluation period to assess safety and determine the maximum tolerated dose (MTD) of ARV-766 and/or recommended Phase 2 dose (RP2D)
Conditions Studied
Interventions
- DRUG ARV-766 Part A&B
- DRUG ARV-766 + Abiraterone Part C&D
Study Locations (20)
California
- Clinical Trial Site - Duarte
- Clinical Trial Site - Fresno
- Clinical Trial Site - La Jolla
- Clinical Trial Site - Orange
- Clinical Trial Site - Santa Monica
New York
- Clinical Trial Site - Buffalo
- Clinical Trial Site - New York
Pennsylvania
- Clinical Trial Site - Philadelphia
- Clinical Trial Site - Pittsburgh
Connecticut
- Clinical Trial Site - New Haven
District of Columbia
- Clinical Trial Site - Washington D.C.
Florida
- Clinical Trial Site - Lake Mary
Illinois
- Clinical Trial Site - Chicago
Louisiana
- Clinical Trial Site - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2021-09-02 |
| Est. Completion | 2027-05-25 |
| Phase | Phase 1 |
What the registry record for NCT05067140 still lists
NCT05067140 is an interventional study that assigns participants to a tested intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap, below the 219-participant average among 17 other Prostate Cancer Metastatic trials with a reported enrollment target (31% lower).
The record links to 1 condition, with Prostate Cancer Metastatic appearing as the primary indexed condition, and to 2 interventions - of which ARV-766 Part A&B is the first listed.
NCT05067140 names 20 study sites across 14 states, led by California, New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05067140 about?
NCT05067140 is a clinical study titled "A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer". A Phase 1/2 study to evaluate the safety and efficacy of ARV-766 given by mouth alone or in combination with abiraterone in men with metastatic prostate cancer.
What is the current status of trial NCT05067140?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 152 participants. The study started on 2021-09-02. Estimated completion is 2027-05-25.
What conditions does trial NCT05067140 study?
This clinical trial studies the following conditions: Prostate Cancer Metastatic.
What interventions are being tested in trial NCT05067140?
The interventions under investigation include: ARV-766 Part A&B (DRUG), ARV-766 + Abiraterone Part C&D (DRUG).
Who is sponsoring clinical trial NCT05067140?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05067140 being conducted?
This trial has 20 study locations across California, Connecticut, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer Metastatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05067140's enrollment target sits among peer trials
152 4th of 17 higher than 14 of 17 other Prostate Cancer Metastatic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer Metastatic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC
ACTIVE NOT RECRUITING · Phase 1
-
Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy
RECRUITING · NA
-
FTT PET/CT in Metastatic Prostate Cancer
RECRUITING
-
Castrate Resistant Prostate Cancer Enhertu Therapy
RECRUITING · Phase 2
-
Exercise in Prostate Cancer
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03328078 · 152 participants · Phase 1
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- NCT04458532 · 152 participants · NA
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
- NCT04858334 · 152 participants · Phase 2
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- NCT04993859 · 152 participants
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI